title: Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia.
abstract: This study investigated the effect of homoharringtonine (HHT) on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia (CML). Fifty-seven patients with CML who could not receive either imatinib or interferon-α were treated with HHT (n = 31) or hydroxycarbamide (HU) (n = 26) to induce and maintain remission, and bone marrow CD34 + CD117 + cells were assayed with flow cytometry. The proportion of CD34 + CD117 + cells was higher in untreated patients (24.7 ± 6.4%) than in donors (4.4 ± 1.1%) and decreased remarkably in patients who had hematological remission (11.2 ± 3.1%) and cytogenetic response (8.9 ± 3.1%) as compared with those without (27.8 ± 7.3% and 18.5 ± 5.3%, respectively) at 12 months after therapy. The hematological remission rate for patients with proportion of CD34 + CD117 + cells ≥ 20% prior to treatment was lower (41.7%) than in patients with CD34 + CD117 + cells < 20% (78.9%; p < 0.05). However, there was no such difference of CD34 + CD117 + cell percentage in the HU group. It can be concluded that high expression of CD117 on CD34 + cells is a marker of poor prognosis and is also a target for the anti-CML effect of HHT.
authors: Department of Hematology, Nanking Medical University, Jiangsu, China. liyufeng99@netease.com
authors: Yu-Feng
authors: YF
authors: Li
authors: Zhikui
authors: Z
authors: Deng
authors: Ban-He
authors: BH
authors: Din
authors: Jian-Bin
authors: JB
authors: Zhu
mesh_terms: D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic; D001854:Bone Marrow Cells / Q000187:drug effects; D015704:CD4 Antigens; D002452:Cell Count; D005260:Female; D005434:Flow Cytometry; D006248:Harringtonines / Q000494:pharmacology* / Q000627:therapeutic use; D000077863:Homoharringtonine; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit; D012074:Remission Induction / Q000379:methods; D055815:Young Adult
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015704:CD4 Antigens; D006248:Harringtonines; D000077863:Homoharringtonine; D019009:Proto-Oncogene Proteins c-kit; D006918:Hydroxyurea